Brokerages expect that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI – Get Rating) will post earnings per share of ($0.54) for the current quarter, according to Zacks. Five analysts have made estimates for Aerie Pharmaceuticals’ earnings, with estimates ranging from ($0.61) to ($0.44). Aerie Pharmaceuticals posted earnings of ($0.67) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 19.4%. The firm is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.33) to ($1.92). For the next fiscal year, analysts expect that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($1.58) to ($1.19). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.01). During the same period last year, the company posted ($0.72) earnings per share.
Several hedge funds and other institutional investors have recently modified their holdings of the company. William Blair Investment Management LLC lifted its position in shares of Aerie Pharmaceuticals by 31.6% during the 3rd quarter. William Blair Investment Management LLC now owns 2,877,149 shares of the company’s stock valued at $32,799,000 after buying an additional 690,649 shares during the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Aerie Pharmaceuticals by 39.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,678,609 shares of the company’s stock valued at $15,275,000 after buying an additional 475,017 shares during the last quarter. Levin Capital Strategies L.P. lifted its position in shares of Aerie Pharmaceuticals by 75.7% during the 1st quarter. Levin Capital Strategies L.P. now owns 1,435,876 shares of the company’s stock valued at $13,066,000 after buying an additional 618,499 shares during the last quarter. Granahan Investment Management Inc. MA lifted its position in shares of Aerie Pharmaceuticals by 0.5% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,394,270 shares of the company’s stock valued at $15,895,000 after buying an additional 6,299 shares during the last quarter. Finally, Schroder Investment Management Group lifted its position in shares of Aerie Pharmaceuticals by 1.5% during the 4th quarter. Schroder Investment Management Group now owns 1,352,954 shares of the company’s stock valued at $9,498,000 after buying an additional 19,990 shares during the last quarter.
Aerie Pharmaceuticals stock traded up $0.36 during trading on Friday, hitting $6.81. 512,084 shares of the company were exchanged, compared to its average volume of 520,899. The business’s 50 day moving average is $8.20 and its 200 day moving average is $8.40. Aerie Pharmaceuticals has a 52 week low of $5.46 and a 52 week high of $19.26. The company has a market capitalization of $331.10 million, a P/E ratio of -4.54 and a beta of 0.74.
About Aerie Pharmaceuticals (Get Rating)
Aerie Pharmaceuticals, Inc, a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension.
- Get a free copy of the StockNews.com research report on Aerie Pharmaceuticals (AERI)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.